Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-κB and MAPK pathways via GLP-1R.
Level 5 - mechanism / opinion, no new human data
Preclinical in vitro laboratory study
PubMed 32702632 · doi:10.1016/j.biopha.2020.110523
What was done
Researchers examined the effects of the GLP-1 receptor agonist liraglutide on osteoclastogenesis using murine bone marrow-derived macrophages (BMMs) and RAW264.7 preosteoclast cells. They assessed GLP-1 receptor (GLP-1R) expression and used GLP-1R knockdown to evaluate its role. Effects on osteoclast formation, bone resorption, and downstream signaling pathways (NF-κB, MAPK, and NFATc1) were evaluated using Western blotting and RT-PCR.
What was found
The abstract reports no numerical values, concentrations, or statistical metrics. The authors observed that GLP-1R was present on BMMs and RAW264.7 cells, and its knockdown increased the expression of osteoclastogenic biomarkers. Liraglutide treatment inhibited osteoclast formation and bone resorption while suppressing NF-κB and MAPK signaling pathways and NFATc1 expression. Knockdown of GLP-1R reversed these inhibitory effects.
Why it matters
This study outlines a cellular mechanism by which GLP-1 receptor agonism may reduce osteoclast-mediated bone resorption, suggesting potential relevance for metabolic bone disorders.
Limits
The study is entirely preclinical and restricted to in vitro murine cell models. No quantitative effect sizes, drug concentrations, or statistical measures are provided in the abstract, and no in vivo animal or human data are included to verify biological efficacy or clinical relevance.
Cited by
- supports GLP-1 receptors are expressed on skeletal muscle cells and bone cells.